Enzo Biochem Price to Free Cash Flow Ratio 2010-2023 | ENZ
Historical price to free cash flow ratio values for Enzo Biochem (ENZ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Enzo Biochem Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-06-05 |
2.21 |
|
0.00 |
| 2023-01-31 |
1.34 |
$-0.57 |
0.00 |
| 2022-10-31 |
2.14 |
$-0.46 |
0.00 |
| 2022-07-31 |
2.37 |
$-0.41 |
0.00 |
| 2022-04-30 |
2.55 |
$-0.25 |
0.00 |
| 2022-01-31 |
3.22 |
$-0.20 |
0.00 |
| 2021-10-31 |
3.44 |
$-0.19 |
0.00 |
| 2021-07-31 |
3.26 |
$-0.08 |
0.00 |
| 2021-04-30 |
3.07 |
$-0.19 |
0.00 |
| 2021-01-31 |
2.82 |
$-0.29 |
0.00 |
| 2020-10-31 |
1.82 |
$-0.39 |
0.00 |
| 2020-07-31 |
2.38 |
$-0.41 |
0.00 |
| 2020-04-30 |
3.02 |
$-0.35 |
0.00 |
| 2020-01-31 |
2.51 |
$0.21 |
11.73 |
| 2019-10-31 |
3.16 |
$0.02 |
150.48 |
| 2019-07-31 |
3.91 |
$-0.07 |
0.00 |
| 2019-04-30 |
3.47 |
$-0.04 |
0.00 |
| 2019-01-31 |
3.76 |
$-0.55 |
0.00 |
| 2018-10-31 |
3.32 |
$-0.28 |
0.00 |
| 2018-07-31 |
4.42 |
$-0.10 |
0.00 |
| 2018-04-30 |
6.00 |
$-0.02 |
0.00 |
| 2018-01-31 |
7.36 |
$0.03 |
253.79 |
| 2017-10-31 |
9.85 |
$0.02 |
456.02 |
| 2017-07-31 |
10.85 |
$-0.04 |
0.00 |
| 2017-04-30 |
8.80 |
$0.70 |
12.61 |
| 2017-01-31 |
6.68 |
$0.62 |
10.77 |
| 2016-10-31 |
6.10 |
$0.82 |
7.48 |
| 2016-07-31 |
6.97 |
$1.11 |
6.30 |
| 2016-04-30 |
4.98 |
$0.42 |
11.83 |
| 2016-01-31 |
4.74 |
$0.45 |
10.57 |
| 2015-10-31 |
3.72 |
$0.22 |
16.86 |
| 2015-07-31 |
3.00 |
$-0.12 |
0.00 |
| 2015-04-30 |
2.80 |
$-0.19 |
0.00 |
| 2015-01-31 |
3.15 |
$-0.10 |
0.00 |
| 2014-10-31 |
5.22 |
$-0.04 |
0.00 |
| 2014-07-31 |
4.80 |
$-0.06 |
0.00 |
| 2014-04-30 |
4.20 |
$-0.12 |
0.00 |
| 2014-01-31 |
2.81 |
$-0.27 |
0.00 |
| 2013-10-31 |
2.49 |
$-0.32 |
0.00 |
| 2013-07-31 |
2.18 |
$-0.28 |
0.00 |
| 2013-04-30 |
2.24 |
$-0.23 |
0.00 |
| 2013-01-31 |
2.89 |
$-0.21 |
0.00 |
| 2012-10-31 |
2.00 |
$-0.17 |
0.00 |
| 2012-07-31 |
1.50 |
$-0.19 |
0.00 |
| 2012-04-30 |
2.74 |
$-0.28 |
0.00 |
| 2012-01-31 |
2.55 |
$-0.28 |
0.00 |
| 2011-10-31 |
2.86 |
$-0.26 |
0.00 |
| 2011-07-31 |
3.84 |
$-0.25 |
0.00 |
| 2011-04-30 |
3.99 |
$-0.19 |
0.00 |
| 2011-01-31 |
4.96 |
$-0.36 |
0.00 |
| 2010-10-31 |
4.31 |
$-0.39 |
0.00 |
| 2010-07-31 |
4.60 |
$-0.44 |
0.00 |
| 2010-04-30 |
5.97 |
$-0.50 |
0.00 |
| 2010-01-31 |
4.74 |
$-0.38 |
0.00 |
| 2009-10-31 |
5.51 |
$-0.48 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
